117 related articles for article (PubMed ID: 10733609)
1. Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models.
Golbraikh A; Bernard P; Chrétien JR
Eur J Med Chem; 2000 Jan; 35(1):123-36. PubMed ID: 10733609
[TBL] [Abstract][Full Text] [Related]
2. 2D & 3D-QSAR Study on Novel Piperidine and Piperazine Derivatives as Acetylcholinesterase Enzyme Inhibitors.
Nazari M; Tabatabai SA; Rezaee E
Curr Comput Aided Drug Des; 2018; 14(4):391-397. PubMed ID: 30047333
[TBL] [Abstract][Full Text] [Related]
3. Automated docking of 82 N-benzylpiperidine derivatives to mouse acetylcholinesterase and comparative molecular field analysis with 'natural' alignment.
Bernard P; Kireev DB; Chrétien JR; Fortier PL; Coppet L
J Comput Aided Mol Des; 1999 Jul; 13(4):355-71. PubMed ID: 10425601
[TBL] [Abstract][Full Text] [Related]
4. A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors.
Tong W; Collantes ER; Chen Y; Welsh WJ
J Med Chem; 1996 Jan; 39(2):380-7. PubMed ID: 8558505
[TBL] [Abstract][Full Text] [Related]
5. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
Chaudhaery SS; Roy KK; Saxena AK
J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
[TBL] [Abstract][Full Text] [Related]
6. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
Akula N; Lecanu L; Greeson J; Papadopoulos V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors.
Liu A; Guang H; Zhu L; Du G; Lee SM; Wang Y
Sci China C Life Sci; 2007 Dec; 50(6):726-30. PubMed ID: 17914643
[TBL] [Abstract][Full Text] [Related]
8. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.
Sippl W; Contreras JM; Parrot I; Rival YM; Wermuth CG
J Comput Aided Mol Des; 2001 May; 15(5):395-410. PubMed ID: 11394735
[TBL] [Abstract][Full Text] [Related]
9. Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Martis EA; Chandarana RC; Shaikh MS; Ambre PK; D'Souza JS; Iyer KR; Coutinho EC; Nandan SR; Pissurlenkar RR
J Biomol Struct Dyn; 2015; 33(5):1107-25. PubMed ID: 24905476
[TBL] [Abstract][Full Text] [Related]
10. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).
Araújo JQ; de Brito MA; Hoelz LV; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
Eur J Med Chem; 2011 Jan; 46(1):39-51. PubMed ID: 21074294
[TBL] [Abstract][Full Text] [Related]
11. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
12. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.
Zhou A; Hu J; Wang L; Zhong G; Pan J; Wu Z; Hui A
J Mol Model; 2015 Oct; 21(10):277. PubMed ID: 26438408
[TBL] [Abstract][Full Text] [Related]
13. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis.
Roy KK; Dixit A; Saxena AK
J Mol Graph Model; 2008 Sep; 27(2):197-208. PubMed ID: 18515163
[TBL] [Abstract][Full Text] [Related]
14. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues.
Recanatini M; Cavalli A; Belluti F; Piazzi L; Rampa A; Bisi A; Gobbi S; Valenti P; Andrisano V; Bartolini M; Cavrini V
J Med Chem; 2000 May; 43(10):2007-18. PubMed ID: 10821713
[TBL] [Abstract][Full Text] [Related]
15. GA strategy for variable selection in QSAR studies: application of GA-based region selection to a 3D-QSAR study of acetylcholinesterase inhibitors.
Hasegawa K; Kimura T; Funatsu K
J Chem Inf Comput Sci; 1999; 39(1):112-20. PubMed ID: 10094610
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
[TBL] [Abstract][Full Text] [Related]
17. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
18. Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches.
Lee S; Barron MG
Toxicol Sci; 2015 Nov; 148(1):60-70. PubMed ID: 26202430
[TBL] [Abstract][Full Text] [Related]
19. The 3D-QSAR study of 110 diverse, dual binding, acetylcholinesterase inhibitors based on alignment independent descriptors (GRIND-2). The effects of conformation on predictive power and interpretability of the models.
Vitorović-Todorović MD; Cvijetić IN; Juranić IO; Drakulić BJ
J Mol Graph Model; 2012 Sep; 38():194-210. PubMed ID: 23073222
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors.
Ul-Haq Z; Mahmood U; Jehangir B
Chem Biol Drug Des; 2009 Dec; 74(6):571-81. PubMed ID: 19843075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
